{"filing":{"accession_number":"0001193125-26-391310","cik":"0001958777","ticker":"FBLG","company_name":"FibroBiologics, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"fblg-20260915.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526391310/fblg-20260915.htm"},"events":[{"id":33460,"run_id":30766,"accession_number":"0001193125-26-391310","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"FibroBiologics entered into a securities purchase agreement to issue 298,508 shares of common stock and accompanying warrants to its Chief Scientific Officer in a private placement under Section 4(a)(2) and Regulation D Rule 506(b), raising approximately $0.5 million. The unregistered securities materially dilute existing shareholder ownership and voting power.","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36911,"accession_number":"0001193125-26-391310","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"FibroBiologics entered into a securities purchase agreement to issue 298,508 shares of common stock and accompanying warrants to its Chief Scientific Officer in a private placement, raising approximately $0.5 million. This is a classic dilutive equity issuance—unregistered sale of equity securities with warrant coverage—which signals capital-raising activity typical of small-cap companies and materially affects shareholder ownership and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:16:50.792582+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36912,"accession_number":"0001193125-26-391310","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This Item 3.02 discloses an unregistered sale of equity securities under Section 4(a)(2) of the Securities Act and Regulation D Rule 506(b), with specific reference to warrants exercisable for 298,508 shares of common stock. The filing explicitly states the securities \"have not been registered under the Securities Act or applicable state securities laws,\" which is the hallmark of a dilutive private placement. The incorporation of Item 1.01 (which typically describes the transaction terms) and the detailed warrant exercise mechanics confirm this is a material capital-raising event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:16:50.792582+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36911,"accession_number":"0001193125-26-391310","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"FibroBiologics entered into a securities purchase agreement to issue 298,508 shares of common stock and accompanying warrants to its Chief Scientific Officer in a private placement, raising approximately $0.5 million. This is a classic dilutive equity issuance—unregistered sale of equity securities with warrant coverage—which signals capital-raising activity typical of small-cap companies and materially affects shareholder ownership and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:16:50.792582+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-09-15"},{"id":36912,"accession_number":"0001193125-26-391310","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This Item 3.02 discloses an unregistered sale of equity securities under Section 4(a)(2) of the Securities Act and Regulation D Rule 506(b), with specific reference to warrants exercisable for 298,508 shares of common stock. The filing explicitly states the securities \"have not been registered under the Securities Act or applicable state securities laws,\" which is the hallmark of a dilutive private placement. The incorporation of Item 1.01 (which typically describes the transaction terms) and the detailed warrant exercise mechanics confirm this is a material capital-raising event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:16:50.792582+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-09-15"}]}